BioSpace News Archive

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London Healthcare Conference on November 21 at 2:40 p.m. GMT (9:40 a.m. EST).

Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has earned two accreditations through ClearHealth Quality Institute’s Telemedicine Accreditation Program (TAP)

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system (CNS) and neuromuscular targets.

DarioHealth Corp. (NASDAQ: DRIO) (“DarioHealth” or “Dario”), a leading, global digital therapeutics company, today announced that Dario’s CEO, Erez Raphael, will be participating in a panel discussion at BTIG Digital Health 2019: Industry Innovators on What’s Next, on Wednesday, November 20, 2019.

CorMedix Inc. announced financial results for the third quarter and nine months ended September 30, 2019 and provided an update on recent business developments.

Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated

The FDA has assigned a Prescription Drug User Fee Act goal date of August 22, 2020 and indicated that it is currently planning to hold a Cardiovascular and Renal Drugs Advisory Committee meeting to discuss the application.

Company announced that it will present updated data from two Phase 1b/2 clinical studies at the 61st American Society of Hematology Annual Meeting (ASH) on December 9, 2019.

Predictive Technology is a leader in the development of genetic and molecular diagnostics and companion therapeutics

New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab’s role in inhibiting itch signals in atopic dermatitis